Results 221 to 230 of about 223,804 (293)

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Serum brain-derived neurotrophic factor, micronutrient status, and inflammatory cytokines in type 2 diabetes with nephropathy: a case-control analysis. [PDF]

PeerJ
Waheed HJ, Numan NA.
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Lactate infusion increases circulating pro-brain-derived neurotrophic factor levels in humans. [PDF]

Front Cell Neurosci
Röja J, Ameller NF, Grip J, Apró W, Moberg M.   +4 more
europepmc   +1 more source

Differential effects of ketamine enantiomers on EEG parameters including the gamma‐delta shift phenomenon

British Journal of Pharmacology, EarlyView.
Background and Purpose Ketamine consists of two enantiomers, (R)‐ketamine and (S)‐ketamine, which exhibit distinct pharmacological properties. Currently, only the (S)‐enantiomer has been approved for the treatment of major depressive disorder, whereas recent clinical studies have failed to demonstrate an antidepressant effect for (R)‐ketamine.
Szabolcs Koncz, Dóra Pothorszki, Noémi Papp, Donát Pál, György Bagdy   +4 more
wiley   +1 more source

The Relationship Between Polycystic Ovary Syndrome (PCOS) and Depression

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder, frequently accompanied by psychological comorbidities including depression. The aim of this narrative review is to summarise the latest research regarding potential contributors to and underpinning mechanisms of this relationship.
Asimina I. Karampela, Maralyn Druce
wiley   +1 more source

Association of diabetes risk reduction diet (DRRD) score with metabolic health, brain-derived neurotrophic factor and adropin in Iranian adults. [PDF]

Nutr J
Rashki A, Moradmand Z, Shahdadian F, Rouhani P, Saneei P.   +4 more
europepmc   +1 more source